Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Inclusion Criteria: 1. 18-70 years, male or female; 2. Subject meets one of the following conditions: 1\) Subject with a history of gout has a serum uric acid ≥480μmol/l at screening; 2) Subject with a history of hyperuricemia has a serum uric acid ≥540μmol/l at screening, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3) Subject with a history of hyperuricemia has a serum uric acid≥480μmol/l at screening, on stable treatment for hypertensive, hyperlipidemia or diabetes for at least 3 month, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3. 18kg/m2≤ BMI ≤32kg/m2. Exclusion Criteria: 1. Subject who is pregnant or breastfeeding; 2. Alanine aminotransferase or Aspartate aminotransferase or total bilirubin\>1.5 upper normal limit; 3. Estimated glomerular filtration rate (MDRD formula) ˂60ml/min; 4. HbA1c˃8%; 5. Subject with known hypersensitivity or allergy to SHR4640 or any component of SHR4640; 6. Subject with a history of malignancy; 7. Subject with a history of urolithiasis, or positive findings on ultrasound examination at screen 8. Subject within the last 3months has: myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia attack; 9. Subject has acute gout flares within 2 weeks before randomization; 10. Subject who is taking any other urate-lowering medication (allopurinol, febuxostat, probenecid and benzbromarone) that is indicated within 2 weeks before randomization and can not stop during the study; 11. Subject who is taking more than 100mg once daily or unstable dosage aspirin within 2 weeks before randomization and can not stop during the study; 12. Subject who is taking any diuretic within 2 weeks before randomization and can not stop during the study.